D rug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight loss results comparable to those of popular GLP-1 injectables like ...

Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...

Novo Nordisk said it is now planning to advance both subcutaneous and oral formulations of amycretin into additional clinical trials. The new data follows another study that showed the ...

Novo Nordisk NVO shares have lost 15.2% so far ... In January, the company reported that patients receiving the highest dose of amycretin experienced a 22% weight loss compared with a gain in ...

The topline results from the Phase 1b/2a clinical trial showed that patients treated with Amycretin achieved ... vice president for Development at Novo Nordisk. "The results seen in the trial ...

As a pioneer in diabetes care, Novo Nordisk NVO claims 34% of the USD ... adding that even if CagriSema is a commercial failure, the firm’s amycretin program (that could enter phase 3 this ...

The early data from UBT251 suggests it may be as similarly fast-acting as another of Novo Nordisk’s obesity hopefuls, the oral GLP-1 and amylin receptor amycretin, which showed 13.1% weight loss ...